# A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Source: https://onco.cc/trials/nct07815665/  
OnCo record `nct07815665` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Ivonescimab, Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Summit Therapeutics, now recruiting.

## Summary

A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma is a phase 2/3 interventional study registered as NCT07815665 by Summit Therapeutics, with 800 participants planned, started 2026-09-10 and due to reach its primary completion in 2030-10-31. Interventions recorded: Ivonescimab Dose 1, enfortumab vedotin (EV), Pembrolizumab, Ivonescimab Dose 2 and Ivonescimab RP3D.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07815665
- Phase: 2/3
- Setting: A Randomized Phase 2/3 Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)
- Sponsor: Summit Therapeutics
- Enrolled: 800

## Sources

- ClinicalTrials.gov NCT07815665: https://clinicaltrials.gov/study/NCT07815665

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Summit Therapeutics](https://onco.cc/companies/summit-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07815665.json